Search

Displaying results 4931 - 4940 of 10000 in total
  1. Drug

    Rattus norvegicus skin

    go.drugbank.com/drugs/DB10608
    Approved

    Rattus norvegicus skin or pelt is used in allergenic testing.

  2. Drug

    Oxyphenisatin acetate

    go.drugbank.com/drugs/DB14627
    ApprovedWithdrawn

    Oxyphenisatin acetate is the pro-drug of [oxyphenisatin] (3,3-bis(4-hydroxyphenyl)-1H-indol-2-one). The FDA withdrew its approval for the use of oxyphenisatin acetate due to safety reasons.[L43942]

  3. Drug

    Flecainide

    go.drugbank.com/drugs/DB01195
    ApprovedInvestigationalWithdrawn

    [L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.[L8875]

    Products: Ag-flecainide, FLECAINIDE EG
  4. Drug

    FP0011

    go.drugbank.com/drugs/DB05090
    Experimental

    It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties. … FP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease).

  5. Drug

    rGLP-1

    go.drugbank.com/drugs/DB05433
    Experimental

    rGLP-1 is a continuous infusion of glucagon-like peptide 1, or GLP-1, targeted for the treatment of congestive heart failure (CHF) in patients ineligible for transplant.

  6. Drug

    Zelquistinel

    go.drugbank.com/drugs/DB19336
    Investigational

    Zelquistinel is under investigation in clinical trial NCT06547489 (GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder).

  7. Drug

    Ingenol disoxate

    go.drugbank.com/drugs/DB15109
    Investigational

    Ingenol disoxate is under investigation in clinical trial NCT02120456 (Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk

  8. Drug

    Epratuzumab

    go.drugbank.com/drugs/DB04958
    Investigational

    This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.

  9. Drug

    Natural Killer Cell

    go.drugbank.com/drugs/DB15721
    Investigational

    Expansion involves the use of feeder cell line systems or bioreactors to enhance the number of NK cells with desired cytotoxicity. … The two maturate variants of NK cells are CD56dim and CD56bright, which exert cytotoxicity through release of toxic chemicals and cytokine secretion, respectively.

  10. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    of Amrubicin [L1714, L1716]. … In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC.